MY199468A - Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof - Google Patents

Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

Info

Publication number
MY199468A
MY199468A MYPI2019001375A MYPI2019001375A MY199468A MY 199468 A MY199468 A MY 199468A MY PI2019001375 A MYPI2019001375 A MY PI2019001375A MY PI2019001375 A MYPI2019001375 A MY PI2019001375A MY 199468 A MY199468 A MY 199468A
Authority
MY
Malaysia
Prior art keywords
steap2
antigen
present
antibodies
binding molecules
Prior art date
Application number
MYPI2019001375A
Other languages
English (en)
Inventor
Thomas Nittoli
Alison Crawford
Jessica R Kirshner
Eric Smith
Lauric Haber
Frank Delfino
John Rudge
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MY199468A publication Critical patent/MY199468A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MYPI2019001375A 2016-09-23 2017-09-22 Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof MY199468A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662399256P 2016-09-23 2016-09-23
PCT/US2017/053111 WO2018058001A1 (en) 2016-09-23 2017-09-22 Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
MY199468A true MY199468A (en) 2023-10-31

Family

ID=60083441

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019001375A MY199468A (en) 2016-09-23 2017-09-22 Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

Country Status (19)

Country Link
US (2) US10772972B2 (OSRAM)
EP (1) EP3515945A1 (OSRAM)
JP (4) JP7078609B2 (OSRAM)
KR (1) KR102520731B1 (OSRAM)
CN (1) CN110088138B (OSRAM)
AU (2) AU2017331361B2 (OSRAM)
BR (1) BR112019005641A2 (OSRAM)
CA (1) CA3037732A1 (OSRAM)
CL (1) CL2019000738A1 (OSRAM)
CO (1) CO2019003923A2 (OSRAM)
EA (1) EA201990781A9 (OSRAM)
IL (2) IL295509A (OSRAM)
MA (1) MA46417A (OSRAM)
MX (1) MX2019003325A (OSRAM)
MY (1) MY199468A (OSRAM)
NZ (1) NZ751906A (OSRAM)
PH (1) PH12019500603A1 (OSRAM)
SG (1) SG10202102617QA (OSRAM)
WO (1) WO2018058001A1 (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
BR112015022585B1 (pt) 2013-03-15 2023-04-04 Regeneron Pharmaceuticals, Inc Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
PL3277725T3 (pl) 2015-03-30 2021-06-14 Regeneron Pharmaceuticals, Inc. Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2016325630B2 (en) * 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
AU2017211120C1 (en) 2016-01-25 2021-10-07 Regeneron Pharmaceuticals, Inc. Maytansinoid derivatives, conjugates thereof, and methods of use
HUE060504T2 (hu) 2016-02-03 2023-03-28 Amgen Res Munich Gmbh PSMA és CD3 bispecifikus T-sejthez kötõ ellenanyag-konstrukciók
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
KR20250114431A (ko) 2016-11-08 2025-07-29 리제너론 파마슈티칼스 인코포레이티드 스테로이드 및 이의 단백질-접합체
CN110944718A (zh) 2017-05-18 2020-03-31 里珍纳龙药品有限公司 环糊精蛋白质药物偶联物
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
JP7366028B2 (ja) 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス，インコーポレーテッド ステロイド及びその抗体コンジュゲート
KR20210008008A (ko) 2018-05-09 2021-01-20 리제너론 파마슈티칼스 인코포레이티드 항-msr1 항체 및 이의 사용 방법
EP3810282A1 (en) 2018-06-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
LT3844189T (lt) 2018-08-31 2025-02-25 Regeneron Pharmaceuticals, Inc. Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą
SG11202103628PA (en) 2018-10-31 2021-05-28 Regeneron Pharma Method and system of identifying and quantifying a protein
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
BR112021010238A2 (pt) 2018-12-19 2021-08-24 Regeneron Pharmaceuticals, Inc. Anticorpos anti-cd28 x anti-cd22 biespecíficos e usos dos mesmos
JP7588586B2 (ja) 2018-12-19 2024-11-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用
WO2020132658A2 (en) 2018-12-21 2020-06-25 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
EP3908323A2 (en) 2019-01-08 2021-11-17 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof
JP7659501B2 (ja) 2019-03-22 2025-04-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ＥＧＦＲｘＣＤ２８多特異性抗体
US11814428B2 (en) * 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
MY190623A (en) 2019-12-06 2022-04-27 Regeneron Pharma Anti-vegf protein compositions and methods for producing the same
CA3160352A1 (en) * 2019-12-06 2021-06-10 Israel Lowy Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
CN115867563B (zh) 2020-06-24 2025-06-27 里珍纳龙药品有限公司 微管溶素及蛋白质-微管溶素偶联物
IL299153A (en) 2020-07-13 2023-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in protein, and their uses
WO2022056329A1 (en) * 2020-09-10 2022-03-17 Immunome, Inc. Snx9 subfamily-targeting antibodies
EP4255487A4 (en) * 2020-12-04 2025-05-28 The University of Chicago Polypeptides for detection and treatment of coronavirus infection
WO2022165171A1 (en) 2021-01-28 2022-08-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
AU2022331241A1 (en) * 2021-08-16 2024-03-28 Regeneron Pharmaceuticals, Inc. Novel il27 receptor agonists and methods of use thereof
WO2023062604A1 (en) * 2021-10-15 2023-04-20 Medimmune, Llc Anti-steap2 chimeric antigen receptors and uses thereof
WO2023129518A1 (en) 2021-12-29 2023-07-06 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
WO2023164510A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-cd28 x anti-psma antibodies
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN116162154B (zh) * 2022-10-21 2024-06-11 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US20250076310A1 (en) 2022-12-08 2025-03-06 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
KR20250133813A (ko) 2022-12-21 2025-09-08 리제너론 파마슈티칼스 인코포레이티드 Adc 접합을 위한 토포이소머라아제 i 억제제의 전구약물 및 이의 사용 방법
EP4661914A1 (en) 2023-02-09 2025-12-17 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates via inverse electron demand diels-alder reactions
EP4665385A2 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
AU2024235165A1 (en) 2023-03-13 2025-09-18 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific anti-cd22 x anti-cd28 molecules
WO2024192308A2 (en) * 2023-03-14 2024-09-19 Xencor, Inc. Anti-cd28 compositions
AU2024252914A1 (en) * 2023-04-11 2025-11-27 Medimmune, Llc Steap2 directed t-cell engagers and compositions thereof
CN120936387A (zh) * 2023-04-11 2025-11-11 免疫医疗有限责任公司 Steap2抗体药物缀合物及其用途
CN120936390A (zh) * 2023-04-12 2025-11-11 阿斯利康(瑞典)有限公司 Steap2靶向化合物及其用途
WO2025014913A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Bispecific pd-l1xcd28 antibodies and methods of use thereof
US20250043017A1 (en) 2023-07-10 2025-02-06 Regeneron Pharmaceuticals, Inc. BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
TW202532433A (zh) * 2023-10-10 2025-08-16 瑞典商阿斯特捷利康公司 Ｔ細胞結合組成物和方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
PT1086223E (pt) 1998-06-01 2009-11-03 Agensys Inc Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações
US20060052321A1 (en) * 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CA2395053C (en) 1999-12-06 2012-05-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
KR20030029847A (ko) * 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
CA2481503A1 (en) * 2002-04-05 2003-10-23 Agensys, Inc. Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
JP5840351B2 (ja) 2002-09-06 2016-01-06 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な９８ｐ４ｂ６と称される、核酸および対応タンパク質
US8784821B1 (en) 2003-05-31 2014-07-22 Amgen Research (Munich) Gmbh Human-anti-human cd3 binding molecules
WO2005079490A2 (en) * 2004-02-13 2005-09-01 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express steap2 polypeptides
JP5064037B2 (ja) 2004-02-23 2012-10-31 ジェネンテック， インコーポレイテッド 複素環式自壊的リンカーおよび結合体
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
NZ573557A (en) 2006-06-02 2010-08-27 Regeneron Pharma High affinity antibodies to human il-6 receptor
AU2007284651B2 (en) * 2006-08-09 2014-03-20 Institute For Systems Biology Organ-specific proteins and methods of their use
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
DK2167963T3 (da) 2007-05-23 2019-06-24 Ventana Med Syst Inc Polymerbærere til immunhistokemi og in situ-hybridisering
BRPI0911442A2 (pt) 2008-04-30 2019-03-12 Immunogen, Inc. conjugados potentes e ligantes hidrofílicos
EP2326349B1 (en) 2008-07-21 2015-02-25 Polytherics Limited Novel reagents and method for conjugating biological molecules
SI2975051T1 (sl) 2009-06-26 2021-08-31 Regeneron Pharmaceuticals, Inc. Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
DK2505654T4 (da) 2010-02-08 2020-07-27 Regeneron Pharma Mus med fælles letkæde
TWI540136B (zh) 2010-04-15 2016-07-01 梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
US20130244905A1 (en) 2010-07-06 2013-09-19 Ed Grabczyk Reporter for RNA Polymerase II Termination
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
MX345538B (es) 2011-05-27 2017-02-03 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6209159B2 (ja) * 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
CA2850096C (en) 2011-10-14 2018-07-03 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
WO2013055990A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
EA026643B1 (ru) 2011-10-14 2017-04-28 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
US9399073B2 (en) 2011-10-14 2016-07-26 Seattle Genetics, Inc. Pyrrolobenzodiazepines
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
CA2857398A1 (en) 2011-12-05 2013-06-13 Igenica Biotherapeutics, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN105142672B (zh) 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
BR112015022585B1 (pt) 2013-03-15 2023-04-04 Regeneron Pharmaceuticals, Inc Composto, composição farmacêutica, conjugado droga-anticorpo, e, uso dos mesmos
JP6608823B2 (ja) 2013-08-26 2019-11-20 レゲネロン ファーマシューティカルス，インコーポレーテッド マクロライドジアステレオマーを含む医薬組成物、その合成方法、及び治療上の使用
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
MY199468A (en) 2016-09-23 2023-10-31 Regeneron Pharma Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

Also Published As

Publication number Publication date
KR102520731B1 (ko) 2023-04-14
JP7695420B2 (ja) 2025-06-18
KR20190067807A (ko) 2019-06-17
AU2017331361B2 (en) 2024-07-18
JP7078609B2 (ja) 2022-05-31
JP2019532056A (ja) 2019-11-07
MX2019003325A (es) 2019-08-05
WO2018058001A1 (en) 2018-03-29
EA201990781A1 (ru) 2019-09-30
EA201990781A9 (ru) 2019-11-27
CN110088138B (zh) 2023-08-25
EP3515945A1 (en) 2019-07-31
SG10202102617QA (en) 2021-04-29
NZ751906A (en) 2025-10-31
PH12019500603A1 (en) 2019-06-03
AU2017331361A1 (en) 2019-04-11
US20200376136A1 (en) 2020-12-03
US11633501B2 (en) 2023-04-25
IL295509A (en) 2022-10-01
CA3037732A1 (en) 2018-03-29
CL2019000738A1 (es) 2019-05-31
US10772972B2 (en) 2020-09-15
MA46417A (fr) 2019-07-31
BR112019005641A2 (pt) 2019-07-30
IL265330A (en) 2019-05-30
AU2024227193A1 (en) 2024-10-31
CO2019003923A2 (es) 2019-04-30
CN110088138A (zh) 2019-08-02
JP2024050697A (ja) 2024-04-10
JP2022091976A (ja) 2022-06-21
US20180104357A1 (en) 2018-04-19
JP2025131732A (ja) 2025-09-09

Similar Documents

Publication Publication Date Title
PH12019500603A1 (en) Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
ZA201901591B (en) Anti¿muc16 (mucin 16) antibodies
MX2025005515A (es) Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
MY195059A (en) Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
JOP20160154B1 (ar) أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
ZA202006504B (en) Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof
WO2011163401A3 (en) Colon and pancreas cancer specific antigens and antibodies
WO2021207242A3 (en) Anti-mesothelin antigen-binding molecules and uses thereof
EA201990779A1 (ru) Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство
TH1901001723A (th) แอนติ-muc16 แอนติบอดี, คอยจูเกตของแอนติบอดี-ยา, และโมเลกุลที่จับกับไบสเปซิฟิกแอนติเจนที่ซึ่งจับ muc16 และ cd3, และการใช้พวกมัน
EA201991227A1 (ru) Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения